Trial Profile
To compare the mobilisation efficiency of biosimilar filgrastim, originator filgrastim, and lenograstim in patients with multiple myeloma in first line therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2017
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary) ; Lenograstim (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 08 Nov 2017 New trial record
- 01 Oct 2017 Results published in the Transfusion